Hear from AstraZeneca at SMi’s HPAPI 2018

London, United Kingdom, January 25, 2018 --(PR.com)-- SMi are delighted to present the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference being held at Holiday Inn, Kensington Forum, London, on the 21st – 22nd May 2018.

Our global panel of speakers will strengthen your knowledge in key topics such as risk assessment, manufacturing in early development, containment and handling issues, waste management, conceptual designs, regulation aspects and the use antibody drug conjugates.

Containment & Conceptual Design of Highly Potent APIs:

Although this emerging market is attractive, it presents a significant challenge for pharmaceutical manufacturers to upgrade existing facilities that are set up to handle only non-potent APIs—the challenge being the major cost associated with the specialized containment needed to ensure that employees and their environment are protected from exposure. Many contract manufacturers are also building new facilities that are designed specifically for the manufacture of HPAPIs, which require a huge investment of millions beyond typical good manufacturing practices production facilities. This investment may include specialized facilities for HPAPI–antibody conjugations that incorporate both potent-compound handling and biologics processing capabilities. *http://bi t.ly/1TMx6Qu

It is important to understand how containing complex production equipment is conducted and trialed, starting from the design process for flexible handling.

Jeff Parry, Senior Formulation Scientist from AstraZeneca will be presenting, "Containment Design to Enable Existing Equipment to Handle HPAPIs" on Day 1 @15:20. Below is an overview of their session:

- How to contain complex production equipment – solutions considered
- Other operator considerations
- How to contain complex production equipment – solutions trialed
- Challenges, solutions and adaptations

When involving highly potent APIs in drug development, there are many facets of consideration to take into account. In terms of routes of containment, an awareness of the target of containment is needed. This will have an impact on, not only whether a specialised facility is needed or not, but also on the integral design features of the facility.

Aurore Perzyna, Head, Production Plan from Oril Industries will be presenting, "Conceptual Design of New HPAPI Facilities: From Lab to Production Scale" on Day 2 @09:50. Below is an overview of their session:

- How to define our target
- Which strategy of containment
- Next steps before building these new facilities

For those looking to attend there is currently a £400 early-bird saving, ending January 31st.

Further information is available at: www.highlypotentapi.com/prc

SMi presents the 2nd Annual:

Highly Potent Active Pharmaceutical Ingredients (HPAPI)
Date: 21st – 22nd May 2018
Workshops: 23rd May 2018
Location: Holiday Inn Kensington Forum, London UK
Website: http://www.highlypotentapi.com/prc

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk